Semi-Continuous Production of LNPs With Microfluidizer Technology

Development and Implementation of Semi-Continuous Production and Analysis Processes to Generate Lipid Nanoparticles Using Microfluidizer^® Technology

We are delighted to present the results of our three year collaboration with Academic and Industry Leaders on Advanced Production Methods of Lipid Nanoparticles called NanoFacT.¹

Cutting-Edge Nanomedicine Manufacturing with a Semi-Continuous Process

In the evolving field of nanomedicine, the production of high-quality nanoparticles is paramount. Traditional batch processes, though effective, often face limitations in processing time, control over particle size as you scale up and Process Analytical Technology implementation. To address these issues, researchers have turned to semi-continuous manufacturing processes. This innovative approach combines the benefits of both batch and continuous methods, offering precise regulation of critical parameters and higher scalability.

Semi-continuous processes enable a constant flow of material with the flexibility of repeated recirculation. This allows the production of various formulations that require different process parameters using the same system configuration. The result is a more efficient and robust manufacturing process that ensures consistent product quality.

The first part of the Microfluidics collaboration addresses the critical factors for the establishment of a temperature-controlled, scalable, semi-continuous manufacturing approach based on the quality by design (QbD) concept.²

The Role of Microfluidizer^® Technology in Nanoparticle Production

A key component in the semi-continuous production of lipid-based nanoparticles is Microfluidizer^® technology. This advanced equipment is designed to achieve consistent, particles with sizes that can be controlled in the range of 50 – 200 nm using high-pressure homogenization. By applying intense, uniform, shear forces, the Microfluidizer^® processor ensures particle size distribution with low polydispersity, which is crucial for the stability and efficacy of nanomedicines. The Interaction Chamber^TM technology within each machine is also inherently scalable, which allows for seamless scale-up from lab scale to production.

The versatility of the Microfluidizer^® technology lies in its ability to handle various materials and formulations. Whether it's solid lipid nanoparticles (SLN) or nanostructured lipid carriers (NLC), the Microfluidizer^® processor can be optimized to achieve the desired particle size and distribution. This adaptability makes it an invaluable tool in the pharmaceutical industry, where precision and consistency are critical.

Enhancing Drug Loading and Stability in Lipid-Based Nanocarriers

One of the primary challenges in nanomedicine manufacturing is achieving high drug loading and stability. Recent research has focused on optimizing the formulation parameters to enhance these critical attributes. For instance, studies have shown that the type of lipids used, the solid to liquid lipid ratio, and the concentration of the drug all play significant roles in determining the encapsulation efficiency (EE%) and loading capacity (LC%).

Real-Time Size Monitoring: Ensuring Consistent Product Quality

Incorporating real-time size monitoring during the production process has been a game-changer.³ Technologies like spatially resolved dynamic light scattering (SR-DLS) provide immediate feedback on particle size, allowing for adjustments in real-time. This ensures that the final product meets the stringent quality standards required for clinical applications.

Ensuring consistent product quality in nanoparticle production is essential for the safety and efficacy of nanomedicines. Real-time size monitoring using SR-DLS technology integrated into the semi-continuous production line offers a significant advantage. This advanced monitoring system provides continuous feedback on particle size, allowing for immediate adjustments to the process parameters.

By detecting potential formulation instabilities such as micelle formation and particle agglomeration early in the production process, SR-DLS helps maintain the desired nanoparticle characteristics. This real-time monitoring capability not only enhances product quality but also increases the efficiency of the manufacturing process.

Design of Experiments: Optimizing Formulation Parameters

To achieve the optimal formulation for nanoparticle production, researchers employ Design of Experiments (DoE) methodologies.⁴ DoE allows for systematic investigation of the effects of various formulation parameters on the final product. By testing different combinations of lipid types, solid to liquid lipid ratios, and drug concentrations, researchers can identify the most influential factors and their interactions.

For example, recent studies have demonstrated that Gelucire^® 43/01 formulations yield higher encapsulation efficiency compared to Precirol^® ATO 5 formulations. Additionally, a higher proportion of liquid lipid introduces imperfections in the crystal lattice, favoring higher drug loading. These insights, gained through DoE, enable the fine-tuning of the production process to achieve the desired nanoparticle characteristics.

Future Prospects and Applications in Nanomedicine

The advancements in semi-continuous production of lipid-based nanoparticles hold immense potential for the future of nanomedicine. The ability to produce high-quality, stable, and consistent nanoparticles on a large scale paves the way for more effective drug delivery systems. This is particularly important for treating diseases that require targeted therapy, such as cancer and neurodegenerative disorders.

As the field of nanomedicine continues to grow, the integration of innovative technologies like the Microfluidizer^® processor and real-time size monitoring will play a crucial role. These advancements not only improve the efficiency and scalability of nanoparticle production but also ensure that the final products meet the highest standards of quality and safety.

In conclusion, the semi-continuous production of lipid-based nanoparticles represents a significant leap forward in nanomedicine manufacturing. By leveraging advanced technologies and optimizing formulation parameters, researchers can develop robust and scalable solutions that promise to revolutionize the way we approach drug delivery and treatment.

References:

¹NanoFacT – Continuous Nanomanufacturing Platform

²Glader, C., Jeitler, R., Wang, Y., Tetyczka, C., Zettl, M., Schl¨omer, M., Caisse, P., Mesite, S., Stephan, S., Bourgeaux, V., Roblegg, E., 2024. Establishment of a semi- continuous nano-production line using the Microfluidizer^® technology for the fabrication of lipid-based nanoparticles part 1: screening of critical parameters and design of experiment optimization studies. Eur. J. Pharmac. Sci. 203. https://doi.org/10.1016/j.ejps.2024.106928.

³Glader, C., Jeitler, R., Wang, Y., van Tuijn, R., Grau-Carbonell, A., Tetyczka, C., Mesite, S., Caisse, P., Khinast, J., Roblegg, E., 2025. Process analytical strategies for size monitoring: offline, At-line, online, and inline methods in a top-down nano- manufacturing line. Pharmaceutics 17, 684. https://doi.org/10.3390/ pharmaceutics17060684.

⁴Glader, C., Jeitler, R., Wang, Y., Urich, J., Tetyczka, C., Caisse, P., Mesite, S., Bourgeaux, V., , Khinast, J., Roblegg, E., 2025. Formulation optimization and real-time size monitoring in the semi-continuous production of edaravone-loaded lipid-based nanocarriers using the Microfluidizer^® technology: Part 2. European Journal of Pharmaceutical Sciences 217, 107306. https://doi.org/10.1016/j.ejps.2025.107306